Asher Biotherapeutics

Asher Bio’s encouraging early data against rival cancer drug sparks $108M financing

Five months after raising $55 million to back a new technology and a promising lead cancer immunotherapy, Asher Biotherapeutics has reeled in $108 million more. CEO Craig Gibbs said investors were enticed by encouraging new data suggesting Asher Bio’s lead program is superior to a competitor's.

By Frank Vinluan

Pharma BioPharma,

Asher Bio adds $55M and takes a page from nature for cancer immunotherapy

Interluekin-2’s use as an immunotherapy has been limited by its severe side effects. Asher Bio is developing a version of IL-2 that the startup’s Chief Technology Officer Andy Yeung said could be more targeted and safer than other approaches.

By Frank Vinluan

The Top Surgical Instruments Needed for Extractions

Discover what tools are essential for efficient, safe surgical extractions in today’s health care landscape, from elevators to forceps and beyond.

By ProdentUSA

The Top-Rated Orthopedic Surgery Centers in the Houston Area and Beyond

Discover Houston's best orthopedic surgery centers and what features — from personalized treatment plans to rehabilitation services — make these top providers stand out in their industry.

By Fondren Orthopedic Group

The Top 6 Best Analytics Tools for Health Care Revenue in 2025

Finding the best analytics tools for health care revenue management can revolutionize operational processes. Compare the leading software options to discover helpful team resources.

By Millennia